A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation

Blood

Volumn 120, Issue 19, 2012, Pages 3875-3881

  Li, Chunfu ^a   Wu, Xuedong ^a   Feng, Xiaoqing ^a   He, Yuelin ^a   Liu, Huaying ^a   Pei, Fuyu ^a   Liao, Jianyu ^a   He, Lan ^a   Shi, Lei ^a   Li, Na ^a   Liu, Qiujun ^a   Liu, Shiting ^a   Chen, Geyu ^a   Su, Qingxia ^a   Ren, Yuqiong ^a   Wang, Yanhua ^a   Tan, Wanxia ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATG FRESENIUS; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HEPARIN; HYDROXYUREA; LEUKOCYTE ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; CHILD; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DRUG DOSE TITRATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; INFANT; LIVER SIZE; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; THALASSEMIA MAJOR;

EID: 84868605177     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-417998     Document Type: Article

References (35)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-487. (Pubitemid 351821761)
2. Neufeld EJ. Update on iron chelators in thalassemia. Hematology Am Soc Hematol Educ Program. 2010;2010:451-455.
3. Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86(5):433-436.
4. Angelucci E, Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica. 2008;93(12):1780-1784.
5. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev. 2008;22(2):53-63. (Pubitemid 351282443)
6. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet. 1982;2(8292):227-229. (Pubitemid 12081767)
7. Gaziev J, Lucarelli G. Hematopoietic stem cell transplantation for thalassemia. Curr Stem Cell Res Ther. 2011;6(2):162-169.
8. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood. 2011;117(5):1745-1750.
9. Irfan M, Hashmi K, Adil S, et al. beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. J Pak Med Assoc. 2008;58(3):107-110. (Pubitemid 351690742)
10. Ghavamzadeh A, Iravani M, Ashouri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant. 2008;14(3):301-308. (Pubitemid 351218201)
11. Kang BW, Moon JH, Chae YS, et al. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. Ann Hematol. 2010;89(8):813-820.
12. La Nasa G, Caocci G, Argiolu F, et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant. 2005;36(11):971-975. (Pubitemid 41741560)
13. Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143(4):548-551.
14. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203. (Pubitemid 39038044)
15. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-751. (Pubitemid 34194843)
16. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427-431.
17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
18. Seghatchian J, Solheim BG. Current opinions on safer red cell transfusion practice and the appropriate use of alternative strategies. Transfus Apher Sci. 2007;37(2):201-207. (Pubitemid 350181586)
19. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421. (Pubitemid 20059509)
20. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci. 2005;1054:186-195. (Pubitemid 43031024)
21. Locatelli F, Littera R, Pagliara D, et al. Outcome of unrelated donor bone marrow transplantation for thalassemia major patients. Paper presented at 53rd ASH Annual Meeting and Exposition, December 11, 2011. San Diego, CA.
22. Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant. 2012;47(1):33-39.
23. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood. 2006;107(7):2984-2992.
24. Mathews V, George B, Lakshmi KM, et al. Improved clinical outcomes of high risk beta-thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with the use of a treosulphan based conditioning regimen and peripheral blood stem cell grafts. Paper presented at 53rd ASH Annual Meeting and Exposition. December 13, 2011. San Diego, CA.
25. Terenzi A, Lubin I, Lapidot T, et al. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation. 1990;50(4):717-720. (Pubitemid 20358556)
26. Rosales F, Naparstek E, Varadi G, Or R, Slavin S, Nagler A. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. Leuk Res. 1999;23(10):947-952. (Pubitemid 29460831)
27. Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotypemismatched hematopoietic transplants. Blood. 2001;97(8):2514-2521. (Pubitemid 32291500)
28. Pakakasama S, Hongeng S, Chaisiripoomkere W, Chuansumrit A, Sirachainun N, Jootar S. Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2004;26(4):248-252. (Pubitemid 38500974)
29. Iravani M, Mousavi A, Gholibeikian S, et al. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2005;35(11):1095-1099. (Pubitemid 40767199)
30. Pidala J, Tomblyn M, Nishihori T, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1237-1244.
31. Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22(3):416-423. (Pubitemid 41079769)
32. Remberger M, Naseh N, Aschan J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003;32(2):217-223. (Pubitemid 36903447)
33. Trachtenberg E, Vinson M, Hayes E, et al. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens. 2007;70(6):455-463. (Pubitemid 350075785)
34. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 2002;99(12):4350-4356. (Pubitemid 34627200)
35. Morishima S, Ogawa S, Matsubara A, et al. Impact of highly conserved HLA haplotype on acute graft-versus-host disease. Blood. 2010;115(23):4664-4670.